Rilotumumab

Summary

Rilotumumab (CHEMBL1743063) is a phase-3 clinical-stage antibody; indicated across 8 conditions including gastric neoplasm and mesothelioma; with CIViC clinical evidence for 1 variant-indication association (e.g. MET Overexpression in stomach carcinoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 8 conditions
• Clinical trials: 8
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743063
Name	Rilotumumab
Type	Antibody
Max phase	3

Also known as: AMG 102, AMG-102, Rilotumumab, RILOTUMUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
mesothelioma	2	MONDO:0005065	EFO:0000588
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
squamous cell lung carcinoma	2	MONDO:0005097	EFO:0000708
gliosarcoma	2	MONDO:0016681	EFO:1001465
glioma	2	MONDO:0021042	MONDO:0100342
small cell lung carcinoma	1	MONDO:0008433	EFO:0000702

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01697072	PHASE3	TERMINATED	First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT02137343	PHASE3	TERMINATED	A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
NCT02926638	PHASE2/PHASE3	TERMINATED	Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
NCT00788957	PHASE1/PHASE2	COMPLETED	Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NCT01039207	PHASE2	COMPLETED	Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01105390	PHASE2	WITHDRAWN	AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
NCT01791374	PHASE1	COMPLETED	Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
NCT02154490	Not specified	COMPLETED	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
MET Overexpression	Stomach Carcinoma	Sensitivity/Response	Rilotumumab	CIViC B	EID5835

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).